<DOC>
	<DOCNO>NCT01923428</DOCNO>
	<brief_summary>This phase 2 , randomize , double blind , placebo-controlled , multi-center study evaluate safety efficacy three dose level AZD1722 subject constipation predominant IBS ( IBS-C ) define ROME III criterion active disease determine two-week screening period . Subjects qualify randomize study receive 5 , 20 , 50 mg AZD1722 BID placebo BID 12 consecutive week . At end treatment period , subject follow additional 4 week .</brief_summary>
	<brief_title>The Efficacy AZD1722 Constipation Predominant Irritable Bowel Syndrome ( IBS-C )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Females male must agree use appropriate method contraception sterile ( appropriate documentation ) Subject ambulatory Subject meet definition IBSC use Rome III Criteria Diagnosis IBS history &lt; 5 SBMs per week Subject meet Screening eligibility criterion ( see ) A colonoscopy base AGA guideline ; every 10 year â‰¥ 50 year old , occurrence warning sign ( i.e. , unexplained weight loss , nonhemorrhoid blood stool ) Ability communicate well Investigator comply requirement entire study , include understanding use touchtone telephone electronic diary . Written inform consent willingness participate study describe . Daily access touch tone telephone . Functional diarrhea define Rome III criterion IBS diarrhea ( IBSD ) , mixed IBS ( IBSM ) , unsubtyped IBS define Rome III criterion Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract within 6 month prior screen , active disease within 6 month prior screen . Including limited cancer , inflammatory bowel disease , diverticulitis , duodenal ulcer , erosive esophagitis , gastric ulcer , pancreatitis ( within 12 month screen ) , cholelithiasis , amyloidosis , ileus , noncontrolled GERD , gastrointestinal obstruction carcinoid syndrome . Use medication know affect stool consistency ( Prohibited Medications ) , include fiber supplement , antidiarrheal , cathartic , antacid , opiate , prokinetic drug , laxative , enema , antibiotic within 4 week enrollment , probiotic ( include probiotic yogurt ) ; salt electrolyte supplement contain sodium , potassium , chloride , bicarbonate formulation seven day prior treatment ; unless specify rescue medication , use accordingly . Clinical evidence significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematologic , neurologic , psychiatric disease may interfere subject successfully complete trial . The subject history current evidence laxative abuse ( clinical judgment physician ) . Hepatic dysfunction ( ALT [ SGPT ] AST [ SGOT ] &gt; 2.5 time upper limit normal ) renal impairment ( serum creatinine &gt; 2mg/dL ) . Any evidence treatment malignancy ( localize basal cell , squamous cell skin cancer cancer situ resect ) within previous year . Any surgery stomach , small intestine colon , exclude appendectomy . Pregnant lactating woman . A major psychiatric disorder ( DSMIIIR DSMIV ) include major depression psychosis require hospitalization last 3 year . History attempt suicide uncontrolled bipolar disorder . Alcohol substance abuse last year . Participation clinical trial within 1 month prior Day 14 ( begin screen period ) . If , opinion Investigator subject unable unwilling fulfill requirement protocol condition , would render result uninterpretable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>